A case of unsuccessful treatment of heparin-induced thrombocytopenia (HIT) with fondaparinux
UMass Chan Affiliations
Meyers Primary Care InstituteDepartment of Medicine, Division of Cardiovascular Medicine
Document Type
Journal ArticlePublication Date
2012-01-01Keywords
ThrombocytopeniaHeparin
Anticoagulants
Cardiovascular Diseases
Health Services Research
Primary Care
Metadata
Show full item recordAbstract
Heparin-induced thrombocytopenia (HIT) is a rare immune-mediated complication associated with unfractionated heparin and to a lesser extent with low-molecular weight heparins. The American College of Chest Physicians recommends treating patients with suspected HIT with a non-heparin product regardless if thrombosis is present. The direct thrombin inhibitors are the preferred agents for the treatment of acute HIT (lepirudin, argatroban [Grade 1C]). Fondaparinux is also suggested as an alternative with a lower level of evidence (Grade 2C). The evidence supporting the use of fondaparinux in the treatment of HIT is limited, but the evidence of fondaparinux causing HIT is even less. We present a case of a patient who developed complications with fondaparinux when used in the acute setting of HIT.Source
Miranda AC, Donovan JL, Tran MT, Gore J. Unsuccessful treatment of heparin induced thrombocytopenia with fondaparinux. J Thromb Thrombolysis 2012;33(1):133-135. DOI: 10.1007/s11239-011-0641-2DOI
10.1007/s11239-011-0641-2Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37139PubMed ID
21947717Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1007/s11239-011-0641-2